Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma

Rennes University Hospital28 enrolled

Overview

Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Ovarian Carcinoma

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Pre-Inclusion Criteria: \- Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT) Inclusion Criteria: * Pathological ovarian carcinoma diagnosed at pathological analysis after surgery. * Neo adjuvant chemotherapy Exclusion Criteria: * no neo-adjuvant chemotherapy * no ovarian carcinoma at final pathological analysis * less than 18 years old.

Locations (1)

Service de Gynécologie

Rennes, France

Outcomes

Primary Outcomes

Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response

Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery.

Time frame: surgery

Secondary Outcomes

Identification of tumoral T cells

Identification of tumoral T cells with FACS analysis of dissociated tumor. Different T cells will be studies: Treg/Th17/Th1/Th2 using antibodies against: CD45/CD3/CD4/CD25/FOXP3 (Treg), CD45/CD3/CD4/IL17A (Th17), CD45/CD3/CD4/CD8/IL4/INF (TCD8 and LTCD4 Th1 et Th2).

Time frame: surgery

Disease Free Survival rate

Time frame: 18 months after surgery

Overall survival rate

Time frame: 18 months after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.